The global osteoarthritis treatment market is expanding rapidly due to an aging population, rising osteoarthritis cases, and continuous research for more effective therapeutics. Explore growth drivers, challenges, and opportunities shaping this dynamic market.

The Osteoarthritis Treatment Market was valued at USD 7.36 Billion in 2024 and is expected to grow from USD 7.79 Billion in 2025 to reach USD 12.28 Billion by 2033, exhibiting a CAGR of 5.86% during the forecast period (2025–2033).

📥 Download Sample Report

Market Overview

Osteoarthritis, often referred to as degenerative arthritis, is the most common long-term joint condition. It leads to stiffness and acute joint pain, with treatments ranging from simple painkillers to advanced injections and therapies. The growing elderly population, increasing osteoarthritis prevalence, and technological advancements in imaging and pain management are driving market expansion. However, the high cost of treatments and side effects of non-steroidal anti-inflammatory drugs (NSAIDs) remain key barriers.

Key Market Growth Drivers

  • Growing Geriatric Population: Osteoarthritis is a leading cause of disability among people aged 65 and above, and the global rise in aging populations is fueling demand for treatments.

  • Increasing Rate of Orthopedic Disorders: Rising obesity, sedentary lifestyles, and knee injuries are contributing to higher osteoarthritis incidence, particularly in weight-bearing joints.

  • R&D Advancements: Novel therapeutics targeting pain relief and disease modification are being developed, such as vanillic acid research aimed at treating synovitis-related knee pain.

Restraining Factor

  • High Cost of Hyaluronic Acid Treatments: Many middle-class patients cannot afford these advanced therapies, limiting accessibility in emerging markets.

Market Opportunities

  • Rising investments in research and development could lead to the first disease-modifying drugs for osteoarthritis, presenting major growth opportunities for pharmaceutical companies.

Regional Insights

  • North America: Holds the largest share, projected to grow at a 5.82% CAGR, driven by rising cases, obesity, and strong awareness campaigns.

  • Asia-Pacific: Fastest-growing region with a 6.28% CAGR, fueled by Japan’s aging population and preference for pain-related treatments.

  • Europe: Increasing elderly population and clinical trials in Germany are pushing demand.

  • South America: Brazil emerging as a strong market with new product launches like DUROLANE injections.

  • Middle East & Africa: GCC nations witnessing growth due to increasing awareness and elderly populations.

Segmentation Insights

  • By Drugs: NSAIDs dominate the market with a projected 5.84% CAGR, followed by corticosteroids and hyaluronic acid injections.

  • By Anatomy: Knee osteoarthritis leads with the highest market share and a 6.25% CAGR, as it is a primary global public health concern.

Key Players

  • Bayer AG

  • OrthogenRx

  • Abbott Laboratories

  • GlaxoSmithKline plc

  • Sanofi SA

  • Pfizer Inc.

  • Zimmer Biomet

  • Anika Therapeutics Inc.

  • Mylan (Viatris)

  • Novartis AG

  • Assertio Holdings Inc.

Recent Developments

  • September 2022: Bayer released updated data on Kerendia (finerenone) for chronic kidney disease and type 2 diabetes patients.

  • December 2021: OrthogenRx was acquired by Avanos Medical for USD 160 million, expanding its Visco supplementation therapy portfolio.

Conclusion

With osteoarthritis cases expected to rise globally, the treatment market is set for steady growth. While high costs remain a challenge, new research and expanding awareness are opening fresh opportunities.

About Us

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/